Name: UMIN ID:
Unique ID issued by UMIN | UMIN000004194 |
---|---|
Receipt number | R000005040 |
Scientific Title | A randomized phase III study of continuous maintenance Bevacizumab with or without Pemetrexed after induction therapy of Carboplatin, Pemetrexed, and Bevacizumab in patients with advanced non-squamous non-small-cell lung cancer whose EGFR mutation status is not active (other than Exon 19 deletion or Exon 21 point mutation) or is not known |
Date of disclosure of the study information | 2010/09/13 |
Last modified on | 2021/10/08 16:34:38 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2010/09/13 11:21:47 | ||
2 | Update | 2011/03/25 12:04:14 | Key inclusion criteria Key inclusion criteria |
|
3 | Update | 2011/03/25 12:06:21 | Address Name of person sending information Name of person sending information Address1 |
|
4 | Update | 2011/06/21 10:32:23 | Organization Organization Category of Funding Organization |
|
5 | Update | 2012/02/14 12:55:44 | Key inclusion criteria Key inclusion criteria Key exclusion criteria |
|
6 | Update | 2012/02/14 18:37:02 | Public title Public title Acronym Acronym |
|
7 | Update | 2012/04/10 09:10:17 | Key inclusion criteria |
|
8 | Update | 2013/03/29 14:08:26 | Key inclusion criteria Key inclusion criteria Key exclusion criteria Key exclusion criteria |
|
9 | Update | 2014/09/17 09:47:56 | Email Name of person sending information Name of person sending information Post marketing survey by drug manufacture etc., specified by Japanese law. |
|
10 | Update | 2015/09/14 16:50:30 | Recruitment status |
|
11 | Update | 2019/03/22 10:08:59 | Recruitment status Date of IRB Last follow-up date |
|
12 | Update | 2019/08/20 16:47:41 | Recruitment status |
|
13 | Update | 2021/10/08 16:34:38 | Recruitment status |